136 related articles for article (PubMed ID: 29276023)
1. Salvage regimens for Hodgkin's lymphoma in the brentuximab vedotin era.
Vitolo U; Chiappella A
Lancet Oncol; 2018 Feb; 19(2):162-163. PubMed ID: 29276023
[No Abstract] [Full Text] [Related]
2. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.
Zinzani PL; Vitolo U; Viviani S; Corradini P; Motta G; Tani M; Cascavilla N; Hohaus S; Merli F; Argnani L; Broccoli A
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):404-8. PubMed ID: 25840816
[TBL] [Abstract][Full Text] [Related]
3. Getting to transplant in Hodgkin lymphoma: BVB.
Gordon LI
Blood; 2018 Jul; 132(1):1-3. PubMed ID: 29976776
[No Abstract] [Full Text] [Related]
4. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.
Zinzani PL; Derenzini E; Pellegrini C; Celli M; Broccoli A; Argnani L
Br J Haematol; 2013 Dec; 163(5):681-3. PubMed ID: 24032977
[No Abstract] [Full Text] [Related]
6. Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.
LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R
Br J Haematol; 2020 May; 189(3):e86-e90. PubMed ID: 32048731
[No Abstract] [Full Text] [Related]
7. Brentuximab vedotin-based salvage treatment in Hodgkin's lymphoma.
Vitolo U; Chiappella A
Lancet Oncol; 2018 Sep; 19(9):1144-1146. PubMed ID: 30122617
[No Abstract] [Full Text] [Related]
8. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
[TBL] [Abstract][Full Text] [Related]
9. Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation.
El Cheikh J; Massoud R; Haffar B; Fares E; Mahfouz R; Jisr T; Kharfan-Dabaja MA; Mougharbel A; Youssef A; Bazarbachi A; Ibrahim A
Leuk Lymphoma; 2017 Nov; 58(11):2745-2747. PubMed ID: 28351183
[No Abstract] [Full Text] [Related]
10. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
Howell M; Gibb A; Radford J; Linton K
Br J Haematol; 2017 Dec; 179(5):841-843. PubMed ID: 27447404
[No Abstract] [Full Text] [Related]
11. Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma.
Haddley K
Drugs Today (Barc); 2012 Apr; 48(4):259-70. PubMed ID: 22536568
[TBL] [Abstract][Full Text] [Related]
12. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma.
Arora A; Bhatt VR; Liewer S; Armitage JO; Bociek RG
Eur J Haematol; 2015 Oct; 95(4):361-4. PubMed ID: 25892213
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
Locatelli F; Mauz-Koerholz C; Neville K; Llort A; Beishuizen A; Daw S; Pillon M; Aladjidi N; Klingebiel T; Landman-Parker J; Medina-Sanson A; August K; Sachs J; Hoffman K; Kinley J; Song S; Song G; Zhang S; Suri A; Gore L
Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
[TBL] [Abstract][Full Text] [Related]
15. Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience.
Sawas A; Ma H; Kuruvilla J; Lue JK; Deng C; Marchi E; Montanari F; Cheng B; Savage KJ; Villa D; Crump M; Connors JM; O'Connor OA
Leuk Lymphoma; 2020 Dec; 61(12):3014-3017. PubMed ID: 32720828
[No Abstract] [Full Text] [Related]
16. Current and emerging treatment options for a patient with a second relapse of Hodgkin's lymphoma.
Kallam A; Armitage JO
Expert Rev Hematol; 2018 Apr; 11(4):293-300. PubMed ID: 29521140
[TBL] [Abstract][Full Text] [Related]
17. Brentuximab vedotin for the treatment of Hodgkin's lymphoma.
Pham A; Chen R
Expert Rev Hematol; 2015 Aug; 8(4):403-12. PubMed ID: 25967932
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.
Kalac M; Lue JK; Lichtenstein E; Turenne I; Rojas C; Amengual JE; Sawas A; Deng C; Mapara MY; Connors JM; Kuruvilla J; O'Connor OA
Br J Haematol; 2018 Mar; 180(5):757-760. PubMed ID: 27984643
[No Abstract] [Full Text] [Related]
19. Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.
Chen R; Chen B
Drug Des Devel Ther; 2015; 9():1729-33. PubMed ID: 25848209
[TBL] [Abstract][Full Text] [Related]
20. Alternative salvage regimens for relapsed/refractory classical Hodgkin's lymphoma.
Magyari F; Barna S; Husi K; Simon Z; Miltényi Z; Váróczy L; Udvardy M; Illés Á
Hematology; 2016 Aug; 21(7):404-10. PubMed ID: 26907830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]